Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

monoclonal gammopathy of uncertain significance (MGUS) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

monoclonal gammopathy of uncertain significance

MONDO:0004225

Also known as:MGUSbenign monoclonal gammopathymonoclonal gammopathy Of undetermined significance (MGUS)

Find Clinical TrialsTrials

Overview

A condition characterized by the presence of a monoclonal gammopathy (MG) in which the clonal mass has not reached a predefined state in which the condition is considered malignant. Up to 25% of cases of monoclonal gammopathy of undetermined significance (MGUS) progress to a B-cell malignancy or myeloma. MGUS may occur in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases.

Clinical Trials40 registered · 21 recruiting

Diagnosis

Biomarker and diagnostic research for monoclonal gammopathy of uncertain significance has been reported in the published literature.

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

40 clinical trials registered, 21 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and biologic therapy. Pipeline includes 7 PHASE2, 1 PHASE1, 9 NA. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06690593](https://clinicaltrials.gov/study/NCT06690593)

Data assembled from 3 of 12 sources · Last updated Sep 21, 2026, 4:53 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are any of the 40 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	53	29%
Disease patterns and progression	37	21%
Laboratory research	27	15%
Patient case studies	26	14%
Testing and diagnosis research	17	9%
Clinical study results	10	6%
Other research	6	3%
New treatment approaches	4	2%

Kisho

monoclonal gammopathy of uncertain significance

Overview

Diagnosis

Research Landscape

Medical References

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

Monoclonal gammopathy of clinical significance: a guide for nephrologists.

Concurrent κ light chain proximal tubulopathy and crystal-storing histiocytosis in monoclonal gammopathy of renal significance: a rare case report with 4-year follow-up and literature review.

Concurrent fabry disease and monoclonal gammopathy of renal significance: a case report.

monoclonal gammopathy of uncertain significance

Overview

Diagnosis

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications

Latest News & Developments

Monoclonal gammopathy of clinical significance: a guide for nephrologists.

Concurrent κ light chain proximal tubulopathy and crystal-storing histiocytosis in monoclonal gammopathy of renal significance: a rare case report with 4-year follow-up and literature review.

Concurrent fabry disease and monoclonal gammopathy of renal significance: a case report.